董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Helen Collins | 女 | Independent Director | 62 | 未披露 | 未持股 | 2025-12-12 |
| Kathleen Sereda Glaub | 女 | Independent Director | 72 | 未披露 | 未持股 | 2025-12-12 |
| Peter Hirth | 男 | Chairman | 74 | 未披露 | 未持股 | 2025-12-12 |
| Christian Elling | 男 | Independent Director | 56 | 未披露 | 未持股 | 2025-12-12 |
| Mai Britt Zocca | 女 | Chief Executive Officer and Director | 58 | 40.93万美元 | 未持股 | 2025-12-12 |
| Heidi Hunter | 女 | Independent Director | 67 | 未披露 | 未持股 | 2025-12-12 |
| David V. Smith | 男 | Independent Director | 65 | 未披露 | 未持股 | 2025-12-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mai Britt Zocca | 女 | Chief Executive Officer and Director | 58 | 40.93万美元 | 未持股 | 2025-12-12 |
| Qasim Ahmad | 男 | Chief Medical Officer | 54 | 未披露 | 未持股 | 2025-12-12 |
| Amy Sullivan | 女 | Chief Financial Officer and Principal Accounting Officer | 55 | 未披露 | 未持股 | 2025-12-12 |
| Devin W. Smith | 男 | General Counsel | 57 | 未披露 | 未持股 | 2025-12-12 |
董事简历
中英对照 | 中文 | 英文- Helen Collins
-
Helen Collins，医学博士，自2017年3月起担任我们的高级副总裁兼首席医疗官。她还于2016年6月至2017年3月担任我们的临床开发Vice President。2013年6月至2016年6月，柯林斯博士在吉利德科学公司担任越来越重要的职务，最近担任吉利德GS-5829BET抑制剂和GS-4059（BTK抑制剂）项目的项目和临床负责人。Collins从2009年11月到2013年5月在Amgen担任多个职位，最近担任肿瘤生物仿制药全球主管。在加入Amgen之前，Collins博士在Redwood Regional Medical Group，或RRMG担任了12年的医疗肿瘤学家和血液学家，并于2006年至2009年担任RRMG的总裁。2005年Collins博士联合创立了非营利的North Bay Cancer Alliance（NBCA），其使命是在旧金山湾区北部的县增加当地获得教育和癌症护理的机会。Collins博士在布林莫尔学院（Bryn Mawr College）获得化学学士学位，在约翰霍普金斯大学医学院（Johns Hopkins University School of Medicine）获得医学博士学位。Collins博士在约翰霍普金斯医院（Johns Hopkins Hospital）完成内科住院医师学位，并在斯坦福大学医学院（Stanford University School of Medicine）完成研究金，在那里她专注于胃肠癌。Collins博士获得肿瘤学和内科的董事会认证。
Helen Collins, M.D. has served as Senior Vice President and Chief Medical Officer since March 2017. She also served as Vice President of Clinical Development from June 2016 to March 2017. From June 2013 to June 2016 Dr. Collins held positions of increasing responsibility at Gilead Sciences, Inc., most recently as Program and Clinical Lead for Gilead's GS-5829 BET inhibitor and GS-4059 (BTK inhibitor) programs. From November 2009 to May 2013 Dr. Collins held positions of increasing responsibility at Amgen, most recently as Global Lead, Oncology Biosimiliars. Prior to joining Amgen, Dr. Collins practiced as a medical oncologist and hematologist for 12 years at Redwood Regional Medical Group, or RRMG, and served as President of RRMG from 2006 to 2009. In 2005 Dr. Collins co-founded the non-profit North Bay Cancer Alliance (NBCA), whose mission is to increase local access to education and cancer care in counties in the northern San Francisco Bay Area. Dr. Collins received a A.B. in Chemistry from Bryn Mawr College and an M.D. from The Johns Hopkins University School of Medicine. Dr. Collins completed her residency in internal medicine at The Johns Hopkins Hospital and completed her fellowship at Stanford University School of Medicine, where she concentrated in gastrointestinal cancer. Dr. Collins is board certified in both oncology and internal medicine. - Helen Collins，医学博士，自2017年3月起担任我们的高级副总裁兼首席医疗官。她还于2016年6月至2017年3月担任我们的临床开发Vice President。2013年6月至2016年6月，柯林斯博士在吉利德科学公司担任越来越重要的职务，最近担任吉利德GS-5829BET抑制剂和GS-4059（BTK抑制剂）项目的项目和临床负责人。Collins从2009年11月到2013年5月在Amgen担任多个职位，最近担任肿瘤生物仿制药全球主管。在加入Amgen之前，Collins博士在Redwood Regional Medical Group，或RRMG担任了12年的医疗肿瘤学家和血液学家，并于2006年至2009年担任RRMG的总裁。2005年Collins博士联合创立了非营利的North Bay Cancer Alliance（NBCA），其使命是在旧金山湾区北部的县增加当地获得教育和癌症护理的机会。Collins博士在布林莫尔学院（Bryn Mawr College）获得化学学士学位，在约翰霍普金斯大学医学院（Johns Hopkins University School of Medicine）获得医学博士学位。Collins博士在约翰霍普金斯医院（Johns Hopkins Hospital）完成内科住院医师学位，并在斯坦福大学医学院（Stanford University School of Medicine）完成研究金，在那里她专注于胃肠癌。Collins博士获得肿瘤学和内科的董事会认证。
- Helen Collins, M.D. has served as Senior Vice President and Chief Medical Officer since March 2017. She also served as Vice President of Clinical Development from June 2016 to March 2017. From June 2013 to June 2016 Dr. Collins held positions of increasing responsibility at Gilead Sciences, Inc., most recently as Program and Clinical Lead for Gilead's GS-5829 BET inhibitor and GS-4059 (BTK inhibitor) programs. From November 2009 to May 2013 Dr. Collins held positions of increasing responsibility at Amgen, most recently as Global Lead, Oncology Biosimiliars. Prior to joining Amgen, Dr. Collins practiced as a medical oncologist and hematologist for 12 years at Redwood Regional Medical Group, or RRMG, and served as President of RRMG from 2006 to 2009. In 2005 Dr. Collins co-founded the non-profit North Bay Cancer Alliance (NBCA), whose mission is to increase local access to education and cancer care in counties in the northern San Francisco Bay Area. Dr. Collins received a A.B. in Chemistry from Bryn Mawr College and an M.D. from The Johns Hopkins University School of Medicine. Dr. Collins completed her residency in internal medicine at The Johns Hopkins Hospital and completed her fellowship at Stanford University School of Medicine, where she concentrated in gastrointestinal cancer. Dr. Collins is board certified in both oncology and internal medicine.
- Kathleen Sereda Glaub
-
Kathleen Sereda Glaub自2019年10月起担任我们的董事会成员。Glaub女士自2018年10月起担任生物技术公司Curasen Therapeutics，Inc.的联合创始人兼执行主席。她还担任生物技术公司Escient Pharmaceuticals，Inc.和丹麦生物技术公司IO Biotech APS的董事会董事。她曾于2014年9月至2019年9月担任上市蛋白质工程公司Codexis，Inc.的董事会成员，并于2013年11月至2016年10月担任生物技术公司Afferent Pharmaceuticals，Inc.的董事会成员。Glaub女士还于2014年8月至2016年10月担任Afferent Pharmaceuticals首席执行官。Glaub女士还在Plexxicon Inc.担任了12年的总裁。此前，她曾担任Cell Genesys，Inc.（一家生物技术公司）的高级副总裁和首席财务官、Genentech，Inc.（一家生物技术公司）的财务主管，以及英特尔公司（一家技术公司）的多种财务和财务职务。Glaub女士在加州大学伯克利分校（University of California，Berkeley）获得文学学士学位，在西北大学凯洛格管理学院（Northwestern University Kellogg School of Management）获得工商管理硕士学位。
Kathleen Sereda Glaub,is co-founder and executive chair for the board of CuraSen Therapeutics, Inc., a biotechnology company, a position she has held since October 2018. From November 2013 until the acquisition of the company by Merck in July 2016, Ms. Glaub served as a director on the board of Afferent Pharmaceuticals. She also served as the Chief Executive Officer of Afferent Pharmaceuticals from August 2014 to October 2016. Previously, she served as president of Plexxikon, Inc. from November 2001 to May 2013. Prior to Plexxikon, Ms. Glaub held positions as senior vice president and chief financial officer of Cell Genesys, Inc., a public biotechnology company, treasurer of Genentech, Inc., a public biotechnology company, and various finance and treasury roles with Intel Corporation, a public technology company. She also serves as a director and chair on the board of Escient Pharmaceuticals, Inc., a private biotechnology company. She previously served on the boards of Codexis, Inc., a publicly traded protein engineering and therapeutics company, and Aligos Pharmaceuticals, Inc., a publicly traded biotechnology company. Ms. Glaub also previously served as a member of the investment advisory board to the Bailard Healthcare Fund. Ms. Glaub received a B.A. from the University of California, Berkeley and an M.B.A. from Northwestern University Kellogg School of Management. - Kathleen Sereda Glaub自2019年10月起担任我们的董事会成员。Glaub女士自2018年10月起担任生物技术公司Curasen Therapeutics，Inc.的联合创始人兼执行主席。她还担任生物技术公司Escient Pharmaceuticals，Inc.和丹麦生物技术公司IO Biotech APS的董事会董事。她曾于2014年9月至2019年9月担任上市蛋白质工程公司Codexis，Inc.的董事会成员，并于2013年11月至2016年10月担任生物技术公司Afferent Pharmaceuticals，Inc.的董事会成员。Glaub女士还于2014年8月至2016年10月担任Afferent Pharmaceuticals首席执行官。Glaub女士还在Plexxicon Inc.担任了12年的总裁。此前，她曾担任Cell Genesys，Inc.（一家生物技术公司）的高级副总裁和首席财务官、Genentech，Inc.（一家生物技术公司）的财务主管，以及英特尔公司（一家技术公司）的多种财务和财务职务。Glaub女士在加州大学伯克利分校（University of California，Berkeley）获得文学学士学位，在西北大学凯洛格管理学院（Northwestern University Kellogg School of Management）获得工商管理硕士学位。
- Kathleen Sereda Glaub,is co-founder and executive chair for the board of CuraSen Therapeutics, Inc., a biotechnology company, a position she has held since October 2018. From November 2013 until the acquisition of the company by Merck in July 2016, Ms. Glaub served as a director on the board of Afferent Pharmaceuticals. She also served as the Chief Executive Officer of Afferent Pharmaceuticals from August 2014 to October 2016. Previously, she served as president of Plexxikon, Inc. from November 2001 to May 2013. Prior to Plexxikon, Ms. Glaub held positions as senior vice president and chief financial officer of Cell Genesys, Inc., a public biotechnology company, treasurer of Genentech, Inc., a public biotechnology company, and various finance and treasury roles with Intel Corporation, a public technology company. She also serves as a director and chair on the board of Escient Pharmaceuticals, Inc., a private biotechnology company. She previously served on the boards of Codexis, Inc., a publicly traded protein engineering and therapeutics company, and Aligos Pharmaceuticals, Inc., a publicly traded biotechnology company. Ms. Glaub also previously served as a member of the investment advisory board to the Bailard Healthcare Fund. Ms. Glaub received a B.A. from the University of California, Berkeley and an M.B.A. from Northwestern University Kellogg School of Management.
- Peter Hirth
-
Peter Hirth自2016年9月起担任公司董事会主席。Hirth博士于2000年创立了Plexxikon，Inc.（一家制药公司），并担任其首席执行官直到2013年5月。Hirth博士目前担任生物制药公司Aligos Therapeutics和生物技术公司Vaxcyte, Inc.的董事会成员，以及几家私人生命科学公司的董事会成员。Hirth博士在德国海德堡大学获得了分子遗传学博士学位，并在加州大学圣地亚哥分校完成了他的博士后工作。
Peter Hirth,founded Plexxikon, Inc., a pharmaceutical company, in 2000 and served as its Chief Executive Officer until May 2013. Dr. Hirth currently serves on the board of directors of Aligos Therapeutics, a biopharmaceutical company, and Vaxcyte, Inc., a biotechnology company, as well as the boards of several private life sciences companies. Dr. Hirth received a Ph.D. in Molecular Genetics from Heidelberg University, Germany and completed his post-doctoral work at the University of California, San Diego. - Peter Hirth自2016年9月起担任公司董事会主席。Hirth博士于2000年创立了Plexxikon，Inc.（一家制药公司），并担任其首席执行官直到2013年5月。Hirth博士目前担任生物制药公司Aligos Therapeutics和生物技术公司Vaxcyte, Inc.的董事会成员，以及几家私人生命科学公司的董事会成员。Hirth博士在德国海德堡大学获得了分子遗传学博士学位，并在加州大学圣地亚哥分校完成了他的博士后工作。
- Peter Hirth,founded Plexxikon, Inc., a pharmaceutical company, in 2000 and served as its Chief Executive Officer until May 2013. Dr. Hirth currently serves on the board of directors of Aligos Therapeutics, a biopharmaceutical company, and Vaxcyte, Inc., a biotechnology company, as well as the boards of several private life sciences companies. Dr. Hirth received a Ph.D. in Molecular Genetics from Heidelberg University, Germany and completed his post-doctoral work at the University of California, San Diego.
- Christian Elling
-
Christian Elling自2015年12月起担任我们的董事会成员。Elling博士于2012年3月加入丹麦工业基金会Lundbeckfonden，并自2017年1月起担任其早期生物技术投资部门Lundbeckfonden Emerge的管理合伙人。自2010年以来，Elling博士在生物技术公司7TM Pharma A/S担任过多个职位，包括之前担任联合创始人，生物与发展副总裁，目前担任首席执行官。Elling博士是NMD Pharma A/S，AFYX Therapeutics A/S和其他几家私人生命科学公司的董事会成员。Elling博士获得了理学硕士学位。他在哥本哈根大学获得了生物化学博士学位和药理学博士学位。
Christian Elling,joined Lundbeckfonden, a Danish-based industrial foundation, in March 2012, and has served as Senior Vice President and Managing Partner of its life science company investment unit, Lundbeckfonden BioCapital, since April 2022. He previously served as a Managing Partner of Lundbeckfonden Emerge, the Company's early stage biotech investment arm, from January 2017 to March 2022. Since 2010, Dr. Elling has served in a number of positions at 7TM Pharma A/S, a biotechnology company, including previously serving as co-founder, Vice President of Biology and Development, and later as Chief Executive Officer. Dr. Elling is a current board member of NMD Pharma A/S, SNIPR Biome and Cytoki Pharma. Dr. Elling received his M.Sc. in Biochemistry and his Ph.D. in Pharmacology from the University of Copenhagen. - Christian Elling自2015年12月起担任我们的董事会成员。Elling博士于2012年3月加入丹麦工业基金会Lundbeckfonden，并自2017年1月起担任其早期生物技术投资部门Lundbeckfonden Emerge的管理合伙人。自2010年以来，Elling博士在生物技术公司7TM Pharma A/S担任过多个职位，包括之前担任联合创始人，生物与发展副总裁，目前担任首席执行官。Elling博士是NMD Pharma A/S，AFYX Therapeutics A/S和其他几家私人生命科学公司的董事会成员。Elling博士获得了理学硕士学位。他在哥本哈根大学获得了生物化学博士学位和药理学博士学位。
- Christian Elling,joined Lundbeckfonden, a Danish-based industrial foundation, in March 2012, and has served as Senior Vice President and Managing Partner of its life science company investment unit, Lundbeckfonden BioCapital, since April 2022. He previously served as a Managing Partner of Lundbeckfonden Emerge, the Company's early stage biotech investment arm, from January 2017 to March 2022. Since 2010, Dr. Elling has served in a number of positions at 7TM Pharma A/S, a biotechnology company, including previously serving as co-founder, Vice President of Biology and Development, and later as Chief Executive Officer. Dr. Elling is a current board member of NMD Pharma A/S, SNIPR Biome and Cytoki Pharma. Dr. Elling received his M.Sc. in Biochemistry and his Ph.D. in Pharmacology from the University of Copenhagen.
- Mai Britt Zocca
-
Mai Britt Zocca自2015年1月起担任公司首席执行官。在成立公司之前，她于2012年1月至2017年1月担任生物技术公司Levoss APS的首席执行官。2011年7月至2019年5月，佐卡博士还是制药公司Onconox APS的创始人兼首席执行官。从2007年7月到2010年12月，Zocca博士还领导Dandrit Biotech A/S，这是一家生物技术公司，担任其首席执行官。Zocca博士目前担任丹麦生物技术贸易组织Dansk Biotek和生物技术公司Valo Therapeutics Ltd.的董事会成员。Zocca博士在哥本哈根大学和美国新华保险的NIH获得生物化学硕士学位和医学博士学位。
Mai Britt Zocca,was the Chief Executive Officer at LevOss ApS, a biotechnology company, from January 2012 until January 2017. Dr. Zocca was also the founder and Chief Executive Officer of OncoNOx ApS, a pharmaceutical company, from July 2011 until May 2019. Dr. Zocca also led DanDrit Biotech A/S, a biotechnology company, as its Chief Executive Officer from July 2007 until December 2010. Dr. Zocca currently serves on the board of directors for Dansk Biotek, a Danish biotechnology trade organization. Dr. Zocca received her M.Sc. in Biochemistry as well as Ph.D. in Medicine from the University of Copenhagen and NIH, NCI, MD, US. - Mai Britt Zocca自2015年1月起担任公司首席执行官。在成立公司之前，她于2012年1月至2017年1月担任生物技术公司Levoss APS的首席执行官。2011年7月至2019年5月，佐卡博士还是制药公司Onconox APS的创始人兼首席执行官。从2007年7月到2010年12月，Zocca博士还领导Dandrit Biotech A/S，这是一家生物技术公司，担任其首席执行官。Zocca博士目前担任丹麦生物技术贸易组织Dansk Biotek和生物技术公司Valo Therapeutics Ltd.的董事会成员。Zocca博士在哥本哈根大学和美国新华保险的NIH获得生物化学硕士学位和医学博士学位。
- Mai Britt Zocca,was the Chief Executive Officer at LevOss ApS, a biotechnology company, from January 2012 until January 2017. Dr. Zocca was also the founder and Chief Executive Officer of OncoNOx ApS, a pharmaceutical company, from July 2011 until May 2019. Dr. Zocca also led DanDrit Biotech A/S, a biotechnology company, as its Chief Executive Officer from July 2007 until December 2010. Dr. Zocca currently serves on the board of directors for Dansk Biotek, a Danish biotechnology trade organization. Dr. Zocca received her M.Sc. in Biochemistry as well as Ph.D. in Medicine from the University of Copenhagen and NIH, NCI, MD, US.
- Heidi Hunter
-
Heidi Hunter，担任卡地纳健康总裁，领导专业解决方案业务。在加入卡地纳健康之前，Hunter女士于2015年9月至2020年9月在UCB担任全球免疫学业务部门高级副总裁。Hunter女士此前还曾在勃林格殷格翰担任生物仿制药业务高级副总裁兼总经理等领导职务，并在艾昆纬担任全球业务合作伙伴关系商业解决方案副总裁等职务。Hunter女士曾在强生旗下公司Centocor担任生物制剂和肿瘤学商业和战略营销方面的高级领导职务。她还曾在美国惠氏（现为辉瑞的一部分）领导肿瘤业务，在丹麦诺和诺德领导女性健康。在亨特职业生涯的早期，她曾在Ciba-Geigy（今天是诺华的一部分）领导神经科学领域的销售和营销工作。Hunter女士目前在Bavarian Nordic A/S、Vicore Pharma Holdings AB和Sutro Biopharma, Inc.的董事会任职。Hunter女士获得了密歇根大学的学士学位和芝加哥大学布斯商学院的硕士学位。
Heidi Hunter,served as President of Cardinal Health, where she led the Specialty Solutions Business. Prior to Cardinal Health, Ms. Hunter served as Senior Vice President of the Global Immunology Business Unit at UCB from September 2015 to September 2020. Ms. Hunter also previously held leadership positions at Boehringer Ingelheim as Senior Vice President and General Manager in its Biosimilars Business, and at IQVIA as Vice President of Global Business Partnerships Commercial Solutions. Ms. Hunter held senior leadership positions in commercial and strategic marketing for biologics and oncology at Centocor, a Johnson & Johnson company. She also led the oncology business at Wyeth (today part of Pfizer) in the United States and Women's Health at Novo Nordisk in Denmark. Early in Ms. Hunter's career, she led sales and marketing at Ciba-Geigy (today part of Novartis) in neuroscience. Ms. Hunter currently serves on the boards of Bavarian Nordic A/S, Vicore Pharma Holdings AB and Sutro Biopharma, Inc. Ms. Hunter earned her B.A. from the University of Michigan and her M. B. A. from the University of Chicago – Booth School of Business. - Heidi Hunter，担任卡地纳健康总裁，领导专业解决方案业务。在加入卡地纳健康之前，Hunter女士于2015年9月至2020年9月在UCB担任全球免疫学业务部门高级副总裁。Hunter女士此前还曾在勃林格殷格翰担任生物仿制药业务高级副总裁兼总经理等领导职务，并在艾昆纬担任全球业务合作伙伴关系商业解决方案副总裁等职务。Hunter女士曾在强生旗下公司Centocor担任生物制剂和肿瘤学商业和战略营销方面的高级领导职务。她还曾在美国惠氏（现为辉瑞的一部分）领导肿瘤业务，在丹麦诺和诺德领导女性健康。在亨特职业生涯的早期，她曾在Ciba-Geigy（今天是诺华的一部分）领导神经科学领域的销售和营销工作。Hunter女士目前在Bavarian Nordic A/S、Vicore Pharma Holdings AB和Sutro Biopharma, Inc.的董事会任职。Hunter女士获得了密歇根大学的学士学位和芝加哥大学布斯商学院的硕士学位。
- Heidi Hunter,served as President of Cardinal Health, where she led the Specialty Solutions Business. Prior to Cardinal Health, Ms. Hunter served as Senior Vice President of the Global Immunology Business Unit at UCB from September 2015 to September 2020. Ms. Hunter also previously held leadership positions at Boehringer Ingelheim as Senior Vice President and General Manager in its Biosimilars Business, and at IQVIA as Vice President of Global Business Partnerships Commercial Solutions. Ms. Hunter held senior leadership positions in commercial and strategic marketing for biologics and oncology at Centocor, a Johnson & Johnson company. She also led the oncology business at Wyeth (today part of Pfizer) in the United States and Women's Health at Novo Nordisk in Denmark. Early in Ms. Hunter's career, she led sales and marketing at Ciba-Geigy (today part of Novartis) in neuroscience. Ms. Hunter currently serves on the boards of Bavarian Nordic A/S, Vicore Pharma Holdings AB and Sutro Biopharma, Inc. Ms. Hunter earned her B.A. from the University of Michigan and her M. B. A. from the University of Chicago – Booth School of Business.
- David V. Smith
-
DavidV.Smith自2016年3月起担任Codexis的董事。Smith先生曾担任Integenx（一家专注于快速DNA识别技术的私人控股公司）的首席运营官，直到2018年3月被Thermo Fisher Scientific收购。任职Integenx公司之前，他曾担任Thoratec Corporation公司（上市公司，专注于开发先进的心脏病治疗方案）的执行Vice President兼首席财务官（从2006年12月到2011年7月）。在2006年加入Thoratec之前，Smith先生曾担任Chiron Corporation的Vice President和首席财务官，他于1999年加入Chiron Corporation，并在该公司担任多个职责递增的职位，包括Vice President、首席会计官和财务总监以及财务Vice President。Smith从1997年到1999年担任Anergen Incorporated金融和首席财务官Vice President。从1988年到1997年，史密斯先生在美国和欧洲的Genentech，Inc.公司担任过多个财务管理职位。他此前曾担任Syntex Corporation、IBM Corporation的财务职务。Smith之前曾担任Oncogenex Pharmaceuticals，Inc.（一家上市生物制药公司）和Perlegen Sciences，Inc.审计委员会主席和董事。他持有Willamette University的经济和历史学士学位，以及Golden Gate University的专攻金融的工商管理硕士学位。
David V. Smith has served as a director of Codexis since March 2016. Mr. Smith served as Chief Operating Officer of IntegenX, a privately held company focused on rapid DNA identification technology, until its acquisition by Thermo Fisher Scientific in March 2018. Prior to IntegenX, he was Executive Vice President and Chief Financial Officer of Thoratec Corporation, a publicly-traded company focused on the development of advanced therapy options for the treatment of heart disease, from December 2006 until July 2011. Prior to joining Thoratec in 2006 Mr. Smith served as Vice President and Chief Financial Officer of Chiron Corporation, which he joined in 1999 and where he held a number of positions of increasing responsibility, including Vice President, Principal Accounting Officer and Controller, and Vice President of Finance. Mr. Smith served as the Vice President of Finance and Chief Financial Officer at Anergen Incorporated from 1997 to 1999. From 1988 to 1997 Mr. Smith served in various financial management positions with Genentech, Inc., both in the United States and Europe. He previously held finance positions at Syntex Corporation and IBM Corporation. Mr. Smith previously served as chair of the Audit Committee and a Director of OncoGenex Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, and of Perlegen Sciences, Inc. He holds a B.A. in Economics and History from Willamette University and an M.B.A. specializing in finance from Golden Gate University. - DavidV.Smith自2016年3月起担任Codexis的董事。Smith先生曾担任Integenx（一家专注于快速DNA识别技术的私人控股公司）的首席运营官，直到2018年3月被Thermo Fisher Scientific收购。任职Integenx公司之前，他曾担任Thoratec Corporation公司（上市公司，专注于开发先进的心脏病治疗方案）的执行Vice President兼首席财务官（从2006年12月到2011年7月）。在2006年加入Thoratec之前，Smith先生曾担任Chiron Corporation的Vice President和首席财务官，他于1999年加入Chiron Corporation，并在该公司担任多个职责递增的职位，包括Vice President、首席会计官和财务总监以及财务Vice President。Smith从1997年到1999年担任Anergen Incorporated金融和首席财务官Vice President。从1988年到1997年，史密斯先生在美国和欧洲的Genentech，Inc.公司担任过多个财务管理职位。他此前曾担任Syntex Corporation、IBM Corporation的财务职务。Smith之前曾担任Oncogenex Pharmaceuticals，Inc.（一家上市生物制药公司）和Perlegen Sciences，Inc.审计委员会主席和董事。他持有Willamette University的经济和历史学士学位，以及Golden Gate University的专攻金融的工商管理硕士学位。
- David V. Smith has served as a director of Codexis since March 2016. Mr. Smith served as Chief Operating Officer of IntegenX, a privately held company focused on rapid DNA identification technology, until its acquisition by Thermo Fisher Scientific in March 2018. Prior to IntegenX, he was Executive Vice President and Chief Financial Officer of Thoratec Corporation, a publicly-traded company focused on the development of advanced therapy options for the treatment of heart disease, from December 2006 until July 2011. Prior to joining Thoratec in 2006 Mr. Smith served as Vice President and Chief Financial Officer of Chiron Corporation, which he joined in 1999 and where he held a number of positions of increasing responsibility, including Vice President, Principal Accounting Officer and Controller, and Vice President of Finance. Mr. Smith served as the Vice President of Finance and Chief Financial Officer at Anergen Incorporated from 1997 to 1999. From 1988 to 1997 Mr. Smith served in various financial management positions with Genentech, Inc., both in the United States and Europe. He previously held finance positions at Syntex Corporation and IBM Corporation. Mr. Smith previously served as chair of the Audit Committee and a Director of OncoGenex Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, and of Perlegen Sciences, Inc. He holds a B.A. in Economics and History from Willamette University and an M.B.A. specializing in finance from Golden Gate University.
高管简历
中英对照 | 中文 | 英文- Mai Britt Zocca
Mai Britt Zocca自2015年1月起担任公司首席执行官。在成立公司之前，她于2012年1月至2017年1月担任生物技术公司Levoss APS的首席执行官。2011年7月至2019年5月，佐卡博士还是制药公司Onconox APS的创始人兼首席执行官。从2007年7月到2010年12月，Zocca博士还领导Dandrit Biotech A/S，这是一家生物技术公司，担任其首席执行官。Zocca博士目前担任丹麦生物技术贸易组织Dansk Biotek和生物技术公司Valo Therapeutics Ltd.的董事会成员。Zocca博士在哥本哈根大学和美国新华保险的NIH获得生物化学硕士学位和医学博士学位。
Mai Britt Zocca,was the Chief Executive Officer at LevOss ApS, a biotechnology company, from January 2012 until January 2017. Dr. Zocca was also the founder and Chief Executive Officer of OncoNOx ApS, a pharmaceutical company, from July 2011 until May 2019. Dr. Zocca also led DanDrit Biotech A/S, a biotechnology company, as its Chief Executive Officer from July 2007 until December 2010. Dr. Zocca currently serves on the board of directors for Dansk Biotek, a Danish biotechnology trade organization. Dr. Zocca received her M.Sc. in Biochemistry as well as Ph.D. in Medicine from the University of Copenhagen and NIH, NCI, MD, US.- Mai Britt Zocca自2015年1月起担任公司首席执行官。在成立公司之前，她于2012年1月至2017年1月担任生物技术公司Levoss APS的首席执行官。2011年7月至2019年5月，佐卡博士还是制药公司Onconox APS的创始人兼首席执行官。从2007年7月到2010年12月，Zocca博士还领导Dandrit Biotech A/S，这是一家生物技术公司，担任其首席执行官。Zocca博士目前担任丹麦生物技术贸易组织Dansk Biotek和生物技术公司Valo Therapeutics Ltd.的董事会成员。Zocca博士在哥本哈根大学和美国新华保险的NIH获得生物化学硕士学位和医学博士学位。
- Mai Britt Zocca,was the Chief Executive Officer at LevOss ApS, a biotechnology company, from January 2012 until January 2017. Dr. Zocca was also the founder and Chief Executive Officer of OncoNOx ApS, a pharmaceutical company, from July 2011 until May 2019. Dr. Zocca also led DanDrit Biotech A/S, a biotechnology company, as its Chief Executive Officer from July 2007 until December 2010. Dr. Zocca currently serves on the board of directors for Dansk Biotek, a Danish biotechnology trade organization. Dr. Zocca received her M.Sc. in Biochemistry as well as Ph.D. in Medicine from the University of Copenhagen and NIH, NCI, MD, US.
- Qasim Ahmad
Qasim Ahmad此前受雇于诺华集团，最近担任诺华肿瘤业务部门高级副总裁、临床开发和医疗事务美国负责人。作为一名训练有素的内科医生和临床肿瘤学家，他为公司带来了二十多年成功的战略临床开发、医疗事务和营销授权方面的专业知识。Ahmad博士在英国伦敦大学伦敦卫生与热带医学学院获得全球卫生政策管理硕士学位，在英国萨里大学获得药物医学硕士学位，在英国伯明翰大学获得临床肿瘤学硕士学位，在巴基斯坦拉合尔旁遮普大学获得医学学位。
Qasim Ahmad,was previously employed by Novartis AG, where he most recently served as Senior Vice President, US Head of Clinical Development & Medical Affairs, for the Novartis Oncology business unit. A trained internist and clinical oncologist, he hass over two decades of successful strategic clinical development, medical affairs, and marketing authorization expertise to the Company. Dr. Ahmad received an MS in Global Health Policy Management from the London School of Hygiene and Tropical Medicine, University of London, United Kingdom, a Master of Pharmaceutical Medicine from University of Surrey, UK, a Master of Clinical Oncology from the University of Birmingham, UK, and his medical degree from the University of Punjab, Lahore, Pakistan.- Qasim Ahmad此前受雇于诺华集团，最近担任诺华肿瘤业务部门高级副总裁、临床开发和医疗事务美国负责人。作为一名训练有素的内科医生和临床肿瘤学家，他为公司带来了二十多年成功的战略临床开发、医疗事务和营销授权方面的专业知识。Ahmad博士在英国伦敦大学伦敦卫生与热带医学学院获得全球卫生政策管理硕士学位，在英国萨里大学获得药物医学硕士学位，在英国伯明翰大学获得临床肿瘤学硕士学位，在巴基斯坦拉合尔旁遮普大学获得医学学位。
- Qasim Ahmad,was previously employed by Novartis AG, where he most recently served as Senior Vice President, US Head of Clinical Development & Medical Affairs, for the Novartis Oncology business unit. A trained internist and clinical oncologist, he hass over two decades of successful strategic clinical development, medical affairs, and marketing authorization expertise to the Company. Dr. Ahmad received an MS in Global Health Policy Management from the London School of Hygiene and Tropical Medicine, University of London, United Kingdom, a Master of Pharmaceutical Medicine from University of Surrey, UK, a Master of Clinical Oncology from the University of Birmingham, UK, and his medical degree from the University of Punjab, Lahore, Pakistan.
- Amy Sullivan
Amy Sullivan，自TABA，BV（一家特殊目的收购公司）加入公司，她于2021年5月开始担任首席财务官。在加入TABA之前，Sullivan女士在2019年1月至2021年5月期间担任泛欧交易所上市公司Kiadis Pharma B.V.的首席战略办公室，该公司是一家生物制药公司，负责融资和资本形成战略的各个方面，在临床失败后重新定位公司，并在公司出售给赛诺菲的过程中发挥了关键作用。在加入Kiadis之前，Sullivan女士于2014年4月至2018年12月期间任职于克律克斯生物制药公司，担任公司事务高级副总裁，负责投资者关系、公司传播和公共事务的各个方面，在高增长期，公司首个FDA批准的药物的商业化以及最终的合并。在加入Keryx之前，Sullivan女士曾在Amag制药，Inc.、β胞核嘧啶制药和Genencor International，B.V.担任企业传播和投资者关系主管。在她职业生涯的早期，沙利文曾在两家机构和《财富》500强公司担任越来越重要的职务。Sullivan女士拥有塞勒姆州立大学商学理学学士学位和本特利大学工商管理硕士学位。
Amy Sullivan,joined the Company from TABA, BV, a special purpose acquisition company, where she served as chief financial officer beginning in May 2021. Prior to her time with TABA, Ms. Sullivan was chief strategy office for Euronext-listed Kiadis Pharma B.V., a biopharmaceutical company from January 2019 until May 2021, where she was responsible for all aspects of fundraising and capital formation strategy, repositioning the company after a clinical failure, and played a critical role in the company's sale to Sanofi. Prior to Kiadis, Ms. Sullivan served Keryx Biopharmaceuticals, Inc. from April 2014 to December 2018 where she was senior vice president of corporate affairs, responsible for all aspects of investor relations, corporate communication, and public affairs, during a period of high growth, commercialization of the company's first FDA-approved medicine and, ultimately, a merger. Prior to Keryx, Ms. Sullivan served as head of corporate communications and investor relations at AMAG Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc., and Genencor International, B.V. Earlier in her career, Ms. Sullivan served in roles of increasing responsibility in both agencies and Fortune 500 companies. Ms. Sullivan has her bachelor of science degree in business from Salem State University and her masters of business administration from Bentley University.- Amy Sullivan，自TABA，BV（一家特殊目的收购公司）加入公司，她于2021年5月开始担任首席财务官。在加入TABA之前，Sullivan女士在2019年1月至2021年5月期间担任泛欧交易所上市公司Kiadis Pharma B.V.的首席战略办公室，该公司是一家生物制药公司，负责融资和资本形成战略的各个方面，在临床失败后重新定位公司，并在公司出售给赛诺菲的过程中发挥了关键作用。在加入Kiadis之前，Sullivan女士于2014年4月至2018年12月期间任职于克律克斯生物制药公司，担任公司事务高级副总裁，负责投资者关系、公司传播和公共事务的各个方面，在高增长期，公司首个FDA批准的药物的商业化以及最终的合并。在加入Keryx之前，Sullivan女士曾在Amag制药，Inc.、β胞核嘧啶制药和Genencor International，B.V.担任企业传播和投资者关系主管。在她职业生涯的早期，沙利文曾在两家机构和《财富》500强公司担任越来越重要的职务。Sullivan女士拥有塞勒姆州立大学商学理学学士学位和本特利大学工商管理硕士学位。
- Amy Sullivan,joined the Company from TABA, BV, a special purpose acquisition company, where she served as chief financial officer beginning in May 2021. Prior to her time with TABA, Ms. Sullivan was chief strategy office for Euronext-listed Kiadis Pharma B.V., a biopharmaceutical company from January 2019 until May 2021, where she was responsible for all aspects of fundraising and capital formation strategy, repositioning the company after a clinical failure, and played a critical role in the company's sale to Sanofi. Prior to Kiadis, Ms. Sullivan served Keryx Biopharmaceuticals, Inc. from April 2014 to December 2018 where she was senior vice president of corporate affairs, responsible for all aspects of investor relations, corporate communication, and public affairs, during a period of high growth, commercialization of the company's first FDA-approved medicine and, ultimately, a merger. Prior to Keryx, Ms. Sullivan served as head of corporate communications and investor relations at AMAG Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc., and Genencor International, B.V. Earlier in her career, Ms. Sullivan served in roles of increasing responsibility in both agencies and Fortune 500 companies. Ms. Sullivan has her bachelor of science degree in business from Salem State University and her masters of business administration from Bentley University.
- Devin W. Smith
Devin W. Smith于2021年6月开始担任生物技术公司Yumanity Therapeutics, Inc.的高级副总裁兼总法律顾问。在Yumanity，他帮助牵头将Yumanity的神经科学资产出售给强生，并与一家私营肿瘤免疫治疗公司进行反向收购。在任职Yumanity之前，Smith先生曾于2018年8月至2021年6月担任Minerva Neurosciences, Inc.高级副总裁兼总法律顾问，负责所有法律、治理和合规事务。在加入Minerva之前，Smith先生曾担任Stallergenes Greer plc的总法律顾问，该公司是一家上市的全球生物制药公司，专注于过敏免疫治疗产品。此前，Smith先生曾领导EMD Serono，Inc.的北美法律部门，该部门是默沙东 KGaA的生物制药部门。史密斯先生在萨福克大学法学院获得法学博士学位，并在北卡罗来纳大学教堂山分校获得学士学位。
Devin W. Smith,had served as Senior Vice President and General Counsel of Yumanity Therapeutics, Inc., a biotech company, beginning in June 2021. At Yumanity, he helped lead the sale of the Yumanity's neuroscience assets to Johnson & Johnson and a reverse merger with a privately held oncology immunotherapy company. Prior to his role at Yumanity, Mr. Smith served as Senior Vice President and General Counsel of Minerva Neurosciences, Inc., from August 2018 to June 2021, where he was responsible for all legal, governance and compliance matters. Before joining Minerva, Mr. Smith served as General Counsel of Stallergenes Greer plc, a publicly traded global biopharmaceutical company focused on allergy immunotherapy products. Previously, Mr. Smith led the North American legal department for EMD Serono, Inc., the biopharmaceutical division of Merck KGaA. Mr. Smith received his J.D. from Suffolk University Law School and his bachelor's degree from the University of North Carolina – Chapel Hill.- Devin W. Smith于2021年6月开始担任生物技术公司Yumanity Therapeutics, Inc.的高级副总裁兼总法律顾问。在Yumanity，他帮助牵头将Yumanity的神经科学资产出售给强生，并与一家私营肿瘤免疫治疗公司进行反向收购。在任职Yumanity之前，Smith先生曾于2018年8月至2021年6月担任Minerva Neurosciences, Inc.高级副总裁兼总法律顾问，负责所有法律、治理和合规事务。在加入Minerva之前，Smith先生曾担任Stallergenes Greer plc的总法律顾问，该公司是一家上市的全球生物制药公司，专注于过敏免疫治疗产品。此前，Smith先生曾领导EMD Serono，Inc.的北美法律部门，该部门是默沙东 KGaA的生物制药部门。史密斯先生在萨福克大学法学院获得法学博士学位，并在北卡罗来纳大学教堂山分校获得学士学位。
- Devin W. Smith,had served as Senior Vice President and General Counsel of Yumanity Therapeutics, Inc., a biotech company, beginning in June 2021. At Yumanity, he helped lead the sale of the Yumanity's neuroscience assets to Johnson & Johnson and a reverse merger with a privately held oncology immunotherapy company. Prior to his role at Yumanity, Mr. Smith served as Senior Vice President and General Counsel of Minerva Neurosciences, Inc., from August 2018 to June 2021, where he was responsible for all legal, governance and compliance matters. Before joining Minerva, Mr. Smith served as General Counsel of Stallergenes Greer plc, a publicly traded global biopharmaceutical company focused on allergy immunotherapy products. Previously, Mr. Smith led the North American legal department for EMD Serono, Inc., the biopharmaceutical division of Merck KGaA. Mr. Smith received his J.D. from Suffolk University Law School and his bachelor's degree from the University of North Carolina – Chapel Hill.